This study investigates advanced pancreatic cancer. It focuses on a therapy using T cells that are engineered to target a specific mutation in the cancer cells.
The study evaluates the safety and activity of this therapy. It looks at how well the therapy works and how it affects the body.
- Who can participate: Adults aged 18 to 75 with advanced pancreatic cancer can participate if they have a specific mutation and meet certain health criteria.
- Study details: Participants will receive a therapy involving modified T cells. Some may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand